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Individualized cancer therapy is a central goal of cancer biologists. Immunotherapy is a rational means to this
end—because the immune system can recognize a virtually limitless number of antigens secondary to the
biology of genetic recombination in B and T lymphocytes. The immune system is exquisitely structured to
distinguish self from non-self, as demonstrated by anti-microbial immune responses. Moreover the immune
system has the potential to recognize self from “altered-self”, which is the case for cancer. However, the immune
system has mechanisms in place to inhibit self-reactive responses, many of which are usurped by evolving
tumors. Understanding the interaction of cancer with the immune system provides insights into mechanisms
that can be exploited to disinhibit anti-tumor immune responses. Here, we summarize the 2012 SITC Primer,
reviewing past, present, and emerging immunotherapeutic approaches for the treatment of cancer—including
targeting innate versus adaptive immune components; targeting and/or utilizing dendritic cells and T cells; the
role of the tumor microenvironment; and immune checkpoint blockade.
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The immune system is able to distinguish self from
non-self, and is able to vigorously attack non-self and
infected self tissues. This is the basis for anti-microbial
responses. The immuno-editing theory suggests that
the immune system is able to recognize and eradicate
subclinical tumors, but at some point equilibrium is
reached and the tumor remains in situ, in a state of
balance with a partially efficacious response [1]. Unfor-
tunately, many tumors escape from this equilibrium
state, and cancer becomes clinically apparent. The goal
of the cancer immunotherapist is to understand the
mechanisms by which cancer is able to escape the
immune system and to therapeutically intervene at crit-
ical points to promote anti-tumor immune responses.
Broadly, such interventions fall under the umbrella of
“immunotherapy” and can include cancer vaccines,
cytokine therapy, the administration of monoclonal
antibodies to block immune checkpoints, and others.
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Innate immunity and inflammation
The innate immune system recognizes pathogens based
on repeated patterns and responds quickly with a variety
of effector mechanisms. This is in contrast to the adaptive
immune system, consisting of T and B cells, which re-
sponds more slowly, but which is more specific. An innate
immune response is often evidenced by Inflammation: a
local response to tissue injury—defined by the presence
of Rubor (redness), Calor (heat), Dolor (pain), and Tumortral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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dicate invasive pathogen; limit the spread of infection; ini-
tiate adaptive immune responses involving T and B cells;
and to initiate tissue repair. Immune responses and in-
flammation are generally advantageous for the host, and
may include suppressing growth of smaller tumors. Inter-
estingly however, inflammation can also promote neoplas-
tic transformation and tumor progression. For example, in
a genetically engineered lung cancer model using mice
with a mutation in K-ras, cigarette smoke induced inflam-
mation and tumor development through the activation of
myeloid cells [2]. In a preclinical model of squamous cell
carcinoma related to HPV E6/E7, chronic inflammation
caused by lymphocytes and Fc Gamma Receptor signaling
on myeloid cells was responsible for malignant transform-
ation, and tumorigenesis could be abrogated via lym-
phocyte depletion or Fc Gamma Receptor blockade [3].
Mutations within tumors can play a role in this process;
BRAF mutations drive tumor cells to produce pro-
inflammatory cytokines like VEGF, IL-10, and IL-6, while
at the same time decreasing expression of anti-tumor
cytokines such as IL-12 [4]. Mutated BRAF also promotes
the secretion of IL-1α and IL-1β, innate inflammatory me-
diators which can drive tumor cells to protect themselves
from immune attack by up-regulating molecules that in-
hibit the function of anti-tumor lymphocytes [5]. Another
molecular mechanism linking chronic inflammation to
cancer progression involves a transcription factor known
as STAT3 (signal transducer and activator of transcription
3). In areas of chronic inflammation, tumors up-regulate
activated (phosphorylated) STAT3, which, in addition to
being anti-apoptotic, drives expression of cytokines that
dysregulate anti-tumor immune responses [6]. Tumors
can also cause systemic immunosuppression as noted in
preclinical models demonstrating an increase in splenic
myeloid suppressor cells, which are a specialized popula-
tion of innate myeloid cells [7,8]. Taken together, these
data provide examples of how the innate immune system
can promote tumor progression, and suggest pathways for
intervention.
Dendritic cells
Dendritic cells (DC) link the innate immune system to
the adaptive immune response. These cells dwell in the
tissues, continually sampling the microenvironment and
taking up antigens primarily through pinocytosis. When
the innate immune system is activated in their vicinity,
DCs sense this as “danger” [9], cease antigen uptake and
travel to local lymph nodes, where their role is to present
antigen to specific T lymphocytes. The microenvironment
in which a DC acquires antigen determines whether the
DC will have the capacity to activate an antigen-specific
lymphocyte or to tolerize the lymphocyte. In addition to
pinocytosis, immature DCs are also able to internalizeantigen through Fc receptor-mediated endocytosis, a pro-
cess in which Fc receptors on the DC bind antibody-
bound antigen. Emerging data suggest that the subtype
of Fc receptor involved in antigen internalization helps
to determine whether the response to that antigen will
be activating or inhibitory [10]. As introduced above, the
ultimate outcome of the lymphocyte-DC interaction is
based primarily on the state of the DC. DCs can produce
distinct cytokine groups that can skew T lymphocytes
toward divergent functions. Moreover, triggering dis-
tinct Toll-like receptors (TLRs) on DCs elicits different
cytokine profiles and different immune responses. Signal-
ing through TLRs 4, 5, or 11 results in DC production of
IL-12, which in turn skews T-cells towards a TH1 pheno-
type capable of promoting anti-tumor immune responses
[11]. Signaling through TLRs 1, 2, or 6 causes DCs to pro-
duce IL-10, which in turn promotes T-cell development
towards regulatory or TH2 phenotypes incapable of pro-
moting anti-tumor immune responses [11]. In mice, a
subset of DCs that express CD8 is primarily responsible
for priming anti-tumor immune responses [12]. Their hu-
man equivalent is thought to be CD141+ DCs [13-16].
These subsets are known to produce IL-12 and cross-
present antigens to lymphocytes.
How can our knowledge of DC biology be used to de-
velop immunotherapy for patients? While it is clear that
activation of these cells is desirable, there are two general
approaches to achieve that end: ex vivo and in vivo activa-
tion. Ex vivo strategies for DC-based immunotherapies
include generation of DCs from circulating monocytes via
subsequent culture, as well as procedures in which DCs
are derived from circulating CD34+ hematopoetic stem
cells (HSCs). In the U.S., an immunotherapy based on
ex vivo activated DCs has been FDA-approved to treat
patients with metastatic prostate cancer. This product,
sipuleucel-T is generated by incubating a patient’s mono-
cytes with a fusion protein that links the target antigen
(Prostatic Acid Phosphatase) to the cytokine GM-CSF;
here GM-CSF serves to mature the monocytes toward
DCs, and assists in internalization of the antigen. After
ex vivo incubation, the mixed cellular product, including
maturing DCs, is re-infused into patients. In a randomized
control trial for prostate cancer patients, this product
resulted in a 4.1 month improvement in median survival
compared to placebo (HR 0.78; P = 0.03) [17]. Another
common strategy for DC-based immunotherapy involves
maturation of immature monocytes into DCs by culturing
them for several days in the presence of GM-CSF and IL-
4. The DCs are then loaded with tumor-specific peptides
or in some variation with whole protein antigens which
they must subsequently process and present [18]. While
ex vivo stimulation of DCs often results in quantifiable
immune and clinical responses with no dose limiting tox-
icities, the overall clinical response rates to this therapeutic
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major strategy under study is to target antigens specifically
to DCs in vivo. This routinely involves the use an adjuvant
(e.g. TLR agonist) in combination with signaling antibodies
(e.g. anti-CD40, anti-DC-SIGN, anti-MMR, anti-DEC-205)
and tumor-specific antigen [20]. In summary, an evolving
understanding of DC biology has led to the first commer-
cially approved cellular immunotherapy for the treatment
(not prevention) of a solid tumor, and further develop-
ments in this field are likely.
Antibodies as therapy
Monoclonal antibodies are now widely utilized in the
treatment of a number of tumor types; pertinent examples
including trastuzumab (anti-Her-2) for the treatment of
breast cancer, rituximab (anti-CD20) for the treatment of
lymphoma, and the recently approved immunoconjugate
T-DM1, which fuses trastuzumab to a highly potent che-
motherapy, emtansine (DM1 [deacetyl maytansine]) to fa-
cilitate local delivery and minimize systemic toxicity [21].
Antibody-based immunotherapeutics can be exquisitely
specific treatment tools, based on the diverse and nano-
molar level affinity of the Fv region of the antibody for its
target, as well as the ability of the Fc region to engage
components of the host immune system. How do mo-
noclonal antibodies work? The mechanisms of action of
unconjugated monoclonal antibodies include blocking a
pro-survival signal, as well as facilitating tumor cell de-
struction by the binding of the Fc portion of the antibody
to Fc Receptors on natural killer (NK) cells—promoting
the ability of NK cells to lyse their targets through a pro-
cess known as antigen-dependent cytotoxicity (ADCC).
Monoclonal antibodies can also mediate cytotoxicity by
binding to complement receptors on effector cells, a
process known as complement-dependent cytotoxicity
(CDCC). The Fc portion of a monoclonal antibody plays
a major role in determining the immune mechanisms in-
duced, with monoclonal antibodies of the human IgG4
isotype primarily functioning as “blockers”. One interest-
ing aspect involved in the development of monoclonal
antibodies for the clinic involves their affinity, while higher
antibody affinity results in increased target engagement
and ADCC, higher affinities can also result in decreased
tumor penetration and compromised efficacy [22-24].
Several recent clinical developments highlight the in-
creasingly prominent role of antibody-based therapy in
cancer. In an important recent result, Yu et al. showed
an 11% absolute benefit in 2-year survival in patients
with advanced neuroblastoma treated with a combin-
ation of IL-2, GM-CSF, and an antibody targeting GD2
(disialoganglioside 2) (P = 0.02) [25]. As discussed above,
a great deal of recent interest involves conjugating
monoclonal antibodies to either a cytotoxic agent, exam-
ples include brentuximab vedotin (anti-CD30-MMAE[monomethyl auristatin E]) for anaplastic large cell and
Hodgkin lymphoma, trastuzumab emtansine (anti-HER2-
DM1) for breast cancer, and glembatumumab vedotin
(anti-GPNMB-MMAE) for breast cancer [21,26,27]. In
addition, T cells can be re-engineered to express chimeric
(antibody-based) antigen receptors (CARs) to target the
powerful killing machinery of cytotoxic lymphocytes dir-
ectly to tumor antigen [28]. CAR transformed T cells have
been developed against a variety of antigens, including
CEA, CAIX, EGFR, HER2, CD19, and CD20, but serious
adverse events have been reported [29,30]. In a particularly
relevant report, Porter et al. recently showed that a CAR
specific for CD19 could mediate a major clinical response
in a patient with chronic lymphocytic leukemia [29]. An-
other fascinating application of monoclonal antibody tech-
nology involves the engineering of bi-specific antibodies,
in which one arm carries specificity for a tumor antigen,
and the other arm is specific for the CD3 complex on
T cells. The idea behind this technology is to physically
co-localize lymphocytes to tumors, inducing anti-tumor
T cell responses. Bi-specific antibodies against CD19
(blinatumomab) have shown promise in Phase I-II studies
[31,32].
Tumor microenvironment
In vivo, a tumor is significantly more complex than a
simple group of clonogenic cells. The three-dimensional
mass that is appreciated on imaging studies contains, in
addition to tumor cells, extracelluar matrix components,
supportive stromal cells (e.g. neovasculature, fibroblasts,
and macrophages), and a number of inflammatory cells.
In terms of mounting an anti-tumor immune response,
there is further complexity involved, since the priming
and effector phases of the immune response are sepa-
rated by time and space. While priming occurs in lymph
nodes, the effector functions must operate within the
tumor mass. Potential barriers to anti-tumor responses
encountered during the priming phase include a paucity
of “danger” signals from innate immune cells, poor re-
cruitment of DCs for cross-presentation, and inadequate
expression of costimulatory ligands on tumor cells or
APCs. Potential barriers to efficacy during the effector
phase involve inadequate recruitment of activated ef-
fector T cells secondary to abnormal vascular endothelial
cells and/or chemokines, the presence of dominant im-
mune inhibitory mechanisms capable of abrogating T
cell effector function (e.g. the inhibitory receptors PD-1
and CTLA-4), extrinsic suppressive cells (TREGs, mye-
loid-derived suppressor cells), metabolic inhibitors (IDO,
arginase), and inhibitory cytokines (IL-10, TGF-β) [33].
The genetic profile of the tumor microenvironment
and its potential correlation with anti-tumor immune re-
sponses has become an area of increased study in recent
years. In one preclinical study of metastatic melanoma,
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ated with CD8+ T cell infiltration [34]. In patients with
metastatic melanoma, the expression of T cell markers
and chemokines correlated with response to a DC-based
vaccine [35]. Likewise, a pro-inflammatory gene expres-
sion profile within the tumor microenvironment was
associated with survival following administration of a
protein-based vaccine in patients with metastatic mel-
anoma [36]. Response to CTLA-4 blockade in patients
with metastatic melanoma was also correlated with ex-
pression of interferon inducible genes and TH1 associ-
ated markers [37]. Finally, expression of T cell homing
genes in the tumor vascular endothelium has also been
implicated in mitigating lymphocyte infiltration [38].
Two important implications of these data include the
potential for improved patient selection for administra-
tion of immunotherapeutics and identifying potential
strategies for improved response to immunotherapies
in patient populations that would otherwise respond
poorly to immunologic interventions.
T cell intracellular signaling
To understand how the adaptive arm of the immune
system is engaged, a basic knowledge of T cell biology
and activation can be helpful. T cells detect antigen
bound to MHC molecules, with the CD4+ T cell subset
binding to MHC Class II primarily expressed on APCs
while CD8+ T cells are activated by binding to MHC
Class I, which can be expressed by APCs as well as nor-
mal cells. Following initial APC-driven activation, CD8+
T cells may later recognize target cells expressing their
cognate antigen, resulting in cell-mediated cytotoxicity.
For T cells to be fully activated, the APC must provide
other signals in addition to the peptide/MHC (signal 1).
The B7-CD28 interaction, with B7 expressed on the APC
and CD28 on T cells, was one of the first co-stimulatory
signaling pathways elucidated [39]. CD28 signaling
is complex, but most likely functions in part by increasing
T cell expression of anti-apoptotic proteins (e.g. Bcl-xL)
and autocrine growth factors like IL-2 [40,41]. Additional
co-stimulatory interactions (APC:T-cell) include OX40L-
OX40, CD70-CD27, CD137L-CD137, and B7RP1-ICOS
[42]. Ultimately, an effective tumor vaccine requires acti-
vating APCs to express appropriate co-stimulatory mole-
cules to promote durable anti-tumor immune responses
through intracellular signaling cascades.
Following T cell engagement with appropriately activa-
ted APCs, intracellular signaling results in activation of
three signaling cascades: NF-AT, NF-kB, and AP-1 [43].
Of these, the NF-AT pathway is particularly interesting,
since NF-AT signaling in the absence of AP-1 results in
immune tolerance, whereas in vivo blockade of NF-AT de-
creases both T cell activation and limits tolerance [44,45].
Recent data showed that the Adenosine 2a Receptor(A2aR) is a component of the negative feedback loop for
T cell activation that is upregulated during T cell activa-
tion, and blockade of A2aR has been shown to increase
the efficacy of tumor vaccines in pre-clinical models [46].
T cell activation is clearly influenced by the spectrum
of cytokines present during antigen recognition, and sev-
eral cytokines exert their immunologic effects by mo-
dulating the function of STAT proteins during T cell
activation. In that regard, STAT4 has thus far been dem-
onstrated to be crucial to T cell mediated anti-tumor
immune responses. IL-12 activates STAT4, which in turn
skews T cells toward a TH1 phenotype and IFN-γ pro-
duction [6]. Recent data show that, in addition to the
canonical pathways such as NF-AT and AP-1, the mTOR
(mammalian target of rapamycin) pathway also plays a
critical role in T cell activation and function. mTOR is
an evolutionarily conserved serine/threonine protein kin-
ase central to integrating nutrient and hormone signaling
pathways [47], which in turn regulates SGK1, a protein
important in epithelial survival. In preclinical models,
SGK1 knockout mice had increased response to tumor
immunotherapy compared to mice with functional SGK1,
suggesting that mTOR up-regulation dampens or inhibits
anti-tumor immunity (unpublished data from Dr. Jonathan
D. Powell, Johns Hopkins University). In summary, T cell
activation is relatively complex, and is generally only par-
tially understood, but plays a critical role in generating an
adaptive anti-tumor immune response.
Memory T-cells
Following initial activation, a minority (5-10%) of T cells
become long-lived memory cells with enhanced func-
tional responses upon antigen re-encounter as compared
to naïve T cells. For cancer immunotherapy the import-
ance of generating functional memory cells is two-fold.
First, the presence of memory cells could potentially de-
crease metastatic spread and prevent tumor re-growth
after an initial response. Second, memory cells could
limit de novo induction of a second malignancy. The im-
portance of tumor infiltrating memory T cells is further
illustrated with the novel Immunoscore, which has dem-
onstrated prognostic and predictive value in colorectal
cancer through the quantification of tumor infiltrating
cytotoxic effector cells and memory T cells [48]. Current
understanding of memory T cells is derived largely from
the study of the immune response to microbes; however,
in the absence of good models of memory induction in
tumor bearing animals or humans, one can reasonably
extrapolate these findings to anti-tumor responses. It
was originally hypothesized that memory T cells were se-
lected randomly from the naïve T cell pool during the
expansion phase of an effector response; but it is now
thought that some T cells are intrinsically more likely
than others to persist after an initial response as memory
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cells express the IL-7 Receptor alpha (IL-7Rα) chain,
CD27 (Tumor Necrosis Factor Receptor Superfamily 7),
BCL-2, and downregulate the effector molecule KLRG1
(Killer Cell Lectin-like Receptor Subfamily G1) [50-52].
However, this expression profile is not exclusive to me-
mory cells, as there are short-lived IL-7Rα+ cells that
also have high expression of KLRG1 [50]. Memory cells
can be divided into three relatively distinct subsets
including: (1) “effector-memory” having more cytotoxic
function; (2) “central-memory” cells, which likely repre-
sent the more classic quiescent memory cell with high
proliferative capacity once re-stimulated; and (3) “tissue-
resident-memory” associated with an organ-specific dis-
tribution in vivo [53].
Multiple models exist for T cell diversification and long-
term cell fate. The Separate-Precursor model, which is less
feasible compared to other models that will be discussed,
states that cells are pre-programmed in the thymus for
subsequent development into a memory cell or an effector
cell [53]. The Decreasing-Potential model postulates that
repetitive exposure to antigen and stimuli drives T cells
away from a memory phenotype towards terminal effector
differentiation [53]. The Signal-Strength model proposes
that memory cell development is dependent on the
overall strength of the signals received by the T cell
through antigen (signal 1), costimulation (signal 2), and
pro-inflammatory cytokines (signal 3) [53]. Finally, the
Asymmetric-Cell-Fate model posits that when a T cell
encounters an APC and divides while still bound to the
APC, the daughter cell that remains attached to the DC
(immunologic synapse) will receive greater signals through
TCR and costimulation resulting in greater potential for
terminal effector differentiation. Conversely, the daughter
cell that is not adjacent to the immunologic synapse will
have greater potential for memory cell differentiation [53].
Differential transcription factor expression is associ-
ated with the memory versus effector transcriptome. T-
bet, BLIMP1, ID2, and STAT4 activity are associated
with effector T cells [53,54]. Similarly, EOMES, BCL-6,
and STAT3 activity are more associated with memory T
cells [53,55]. Contemporary modeling supports a graded
expression of these transcription factors resulting ultim-
ately in the final lymphocyte phenotype. Additionally,
there are metabolic differences between memory and ef-
fector T cells. Interestingly, memory cells—being more
quiescent as compared to effector T cells—sustain ATP
through fatty acid oxidation, whereas effector T cells
utilize aerobic glycolysis and lipid synthesis [56]. In that
regard, mTOR is at least partially responsible for the
aerobic metabolism found in effector T cells [57].
When T cells are continually exposed to antigen, as is
often the case for lymphocytes specific for tumor-associ-
ated antigens, there exists the potential for such T cells tobecome “exhausted”. T cell exhaustion is characterized by
loss of effector cytokine production (IL-2, TNF-α, and
IFN-γ), impaired proliferation, and decreased cytotoxicity.
Whereas memory T cells require IL-7 and IL-15 for main-
tenance, exhausted T cells appear to be maintained via
continued exposure to antigen. Exhausted T cells also have
a distinct transcriptome with upregulation of BLIMP1,
EOMES, BATF and down-regulation of T-bet. Further-
more, exhausted lymphocytes express negative regulatory
surface molecules including PD-1, LAG-3, TIM-3, 2B4,
and CD160 [58]. Exhaustion is clearly reversible in some
cases, as PD-1 blockade in a viral model of exhaustion was
able to rescue the T cells from their exhausted phenotype
[59], and blocking these immune checkpoint molecules
associated with exhaustion is showing promise in multiple
clinical trials [60]. Taken together, these new insights into
memory cell differentiation and function offer multiple
novel avenues for intervention in terms of generating a
productive anti-tumor response.
Tumor antigens and immunogenicity
T cells recognize antigen in the form of small peptides,
derived from proteolysed substrates, and presented in
the context of MHC molecules. MHC molecules are
genetically diverse, and for each MHC variant, only spe-
cific peptide sequences from a given antigen are able to
bind for presentation to T cells and subsequent induc-
tion of anti-tumor immune responses. Understanding the
specific antigens recognized by the immune system and
the specific peptide sequences presented on MHC can be
important in improving immunotherapies directed against
a specific antigen. Several approaches have been used to
identify tumor specific antigens, including molecular clon-
ing; sequencing of antigenic peptides; and computer al-
gorithms, each of which has its relative benefits and
deficiencies.
Multiple processing pathways exist for proteolysis of
antigen through the proteosome and presentation in
MHC molecules [61]. Determinants of a peptide’s ability
to induce an immune response (i.e. its “antigenicity”) in-
clude its affinity to the MHC, as well as the affinity of
the peptide/MHC complex for a given T Cell Receptor
(TCR). A critical facet of this interaction is a set of
amino acids which are integral to MHC binding, so-
called MHC-anchor-residues. To induce more robust
immune responses, it is possible to modify antigenic
peptides in several ways. MHC variable peptides (MVP),
for example, are peptides designed with amino acid
point changes involving MHC-contact residues, usually
optimized for improved MHC affinity. Conversely, al-
tered peptide ligands (APL) are peptides with amino acid
substitutions designed to optimize interactions with the
T cell receptor. These altered peptides have been used
in an attempt to augment immune response against a
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both the preclinical and clinical setting resulting in im-
proved immunogenicity for a number of tumor antigens,
including gp100, CEA, and NY-ESO/LAGE-1 [63-65]. Un-
derstanding the specific antigen/peptide associated with
anti-tumor immune responses allows for monitoring of
ongoing immunologic responses with ex vivo studies in-
cluding enumeration via tetramer and functionality via
IFN-γ production, ELISPOT, lytic activity, functional avid-
ity, and replicative history assayed via enumerating telo-
mere length.
The term “cancer vaccine” encompasses a variety of
approaches sharing the common goal of activating and
expanding a population of specific T cells to generate an
anti-tumor response. A variety of vaccine approaches
have been explored, including synthetic peptides, recom-
binant virus-like particles (VLP), naked/stabilized nu-
cleic acids, recombinant viruses, recombinant bacteria,
and dendritic cells. One notable facet of cancer vaccines
is that they must provide antigen (signal 1) in addition
to a second signal (signal 2) to elicit full effector function.
The addition of an appropriate adjuvant to a vaccine (i.e. a
“danger” signal [9]), can be important in providing Signal
2. Despite a great deal of work, only two cancer vaccines
have been approved for clinical use, including Oncophage
(Russia, 2008) and Provenge (sipuleucel-T) (USA, 2010).
The PSA-targeting viral vaccine ProstVac VF is currently
in phase III trials worldwide [17,66]. Although monitoring
vaccine responses in peripheral blood is challenging, re-
cent studies suggest that patients treated with sipuleucel-T
do mount detectable antigen-specific T and B cells respon-
ses, which correlate to some degree with outcome [67].
Clinically, single agent efficacy of most cancer vaccines
is less obvious, with objective clinical responses rarely
detected [68]. Although multiple mechanisms may un-
derlie this observation, data showing expression of im-
mune checkpoint molecules like PD-1 and CTLA-4 on
tumor-specific lymphocytes suggests that combining im-
mune checkpoint blockade with vaccination might be one
way to optimize a vaccine-initiated anti-tumor immune
response [69].
Coinhibition and costimulation in cancer immunotherapy
As discussed above, the T-cell/APC interaction involves
engagement of the TCR with the antigen-MHC complex;
in addition, costimulation/coinhibition interactions also
occur and these secondary receptor/ligand binding events
ultimately affect downstream T cell responses. Classic-
ally, costimulation involves the interaction of B7-
CD28–disruption of this interaction by CTLA-4 expression
on T cells, with associated tight binding to B7 is
referred to as co-inhibition [39,70]. Early preclinical stud-
ies demonstrated that blockade of CTLA-4 could mitigate
inhibition of anti-tumor immune responses [71]. Thisfinding was eventually confirmed clinically in Phase III
trials in patients with metastatic melanoma [72]. In add-
ition to CTLA-4, tumor infiltrating lymphocytes may
express the negative regulatory receptors PD-1, LAG-3,
TIM-3 and others [73-75]. Preclinical blockade of these
pathways results in improved anti-tumor immunity [76-78].
Interestingly, a single tumor-infiltrating lymphocyte may
express multiple immune checkpoint molecules simultan-
eously, so it is not surprising that combined blockade sug-
gests improved efficacy in preclinical models [77]. The
ligand for PD-1 is PD-L1, and expression of PD-L1 in tu-
mors correlated with patient response to anti-PD-1 ther-
apy [79]. These data would suggest that there could be
potential biomarkers for checkpoint blockade therapy.
Current preclinical studies are combining checkpoint
blockade with tyrosine kinase inhibitors, radiation therapy
and cancer vaccines.
Adoptive cellular therapy
Adoptive T cell therapy allows for ex vivo stimulation of
lymphocytes in a non-tolerizing environment followed
by re-infusion of activated T cells into patients. There
are varying sources and types of T cells used for adoptive
therapy, these include tumor infiltrating lymphocytes
(TILs), T cells engineered to express a cancer-specific
TCR, and T cells engineered to express a chimeric anti-
gen receptor (CAR) that combines the extracellular por-
tion of an antibody with the T cell receptor signaling
machinery. Of these approaches, expanded TILs are the
least labor intensive to produce, yet require an invasive
procedure to obtain. Additionally, maintenance of TILs
after adoptive transfer usually requires high dose IL-2,
which results in significant toxicity. Clinical response
rates in patients with metastatic melanoma treated with
expanded TILs is impressive, approximately 50% in
several studies [80]. Furthermore, pretreatment of
patients with lymphodepletion can result in a greater
proportion of clinical responses and more durable
responses [81]. As previously discussed, host T cells
can be re-engineered to express CAR in place of the
TCR. The CAR expresses an antibody Fv region in
place of the extracellular domain of the TCR allowing
the T cell to recognize whole antigen as opposed to
MHC-restricted antigen [82]. This approach is effi-
cient and results in T cells with uniform specificity,
but is limited to some degree by transduction effi-
ciency and potential toxicity. Another approach to
adoptive T cell therapy is the use of endogenous
tumor-specific T cells. This approach involves pheresis
of circulating tumor-specific T cells, in vitro expan-
sion and activation, and lastly reintroduction into the
host via adoptive transfer [83]. This approach is con-
sidered to be the most physiologic, but is most labor
intensive as it involves multiple pheresis sessions and
Harris and Drake Journal for ImmunoTherapy of Cancer 2013, 1:12 Page 7 of 9
http://www.immunotherapyofcancer.org/content/1/1/12significant laboratory labor for the expansion and
activa-tion steps. Given the recent high-profile success
of chimeric antigen receptor modified T cells for patients
with CLL, these approaches are attracting increasing
attention and enthusiasm [29,84].Conclusions
The immune system is exquisitely poised to recognize
and distinguish self from non-self. Further, the immune
system is able to recognize self from “altered-self”, which
is the case for cancer. Although clinically apparent malig-
nancies have likely circumvented endogenous anti-tumor
immune responses, immunotherapy has the potential to
augment responses in order to mitigate tumor progres-
sion. As reviewed above, immune responses can be di-
vided between innate and adaptive responses. Innate
immune responses recognize general patterns of non-self
(e.g. double-stranded RNA, single-stranded DNA, LPS)
and are able to initiate pro-inflammatory responses which
in turn can attract immune components leading to adap-
tive immunity. Adaptive immunity is defined by acquired
immunity to specific antigens, and is mediated through
B cells via antibody secretion and T cells through cell-
mediated immunity. Dendritic cells are antigen present-
ing cells which function at the crossroads of innate and
adaptive immunity and are able to cross-present antigen
to, and activate, T cells. Dendritic cells are a target of vari-
ous immunotherapeutic approaches either through the
use of adjuvant cytokines which activate dendritic cells or
more directly through the use of dendritic cell vaccines.
Antibodies produced by B cells are highly specific for cog-
nate antigen and have been engineered through various
mechanisms to simultaneously target the tumor antigen
and potentiate anti-tumor immune responses. T cells
are ultimately responsible for cell-mediated immune re-
sponses, which are thought to be the most important
mechanism of immune related tumor killing for solid
malignancies. T cells can be activated through antibody
blockade of inhibitory signaling, vaccination, or ex vivo
stimulation followed by adoptive transfer into patients.
A more complete understanding of the cellular and
molecular components of the tumor-immune system
interaction is crucial to the development of rational and
efficacious immunotherapies in the future. This primer
serves as a starting point for the cancer biologist and bud-
ding immunotherapist to better understand and appreciate
the past, present, and future of immunotherapeutics.
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